Urology Times Innovation Celebration: Expert Insights

William J. Catalona, MD, explains how prostate-specific antigen (PSA) testing revolutionized screening and treatment of prostate cancer.

In this installment of our 50th Anniversary Innovation Celebration, Amy Pearlman, MD, interviews Mohit Khera, MD, MBA, MPH, on how advancements in testosterone therapy have changed treatment modalities across urology, providing patients with more efficacious, individualized care.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the innovative use of stem cell–derived treatments in urologic conditions such as stress urinary incontinence.

In this interview, Anthony Atala, MD, discusses how regenerative medicine and tissue engineering have greatly improved the quality of life for patients who have undergone urologic surgery.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Howard Goldman, MD, discusses the development of the midurethral sling as a treatment for stress urinary incontinence.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Veda N. Giri, MD, highlights the role genetic testing has played in a new era of prostate cancer therapeutics.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, John Stoffel, MD, discusses the development of clean intermittent catheterization and how it has improved the care of patients with urologic conditions.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Arthur L. Burnett, MD, MBA, FACS, discusses how sildenafil citrate (Viagra) has been an integral part of erectile dysfunction management for decades.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kara L. Watts, MD, discusses the emergence and increasing uptake of active surveillance as a management strategy for men with prostate cancer.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the critical role that BCG has played in managing bladder cancer, and how the BCG shortage continues to evolve.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, James E. Lingeman, MD, discusses the development of extracorporeal shock wave lithotripsy for the treatment of kidney stones.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Rachel S. Rubin, MD, discusses the evolution in the treatment of female hypoactive sexual desire disorder.

"Throughout the years, I've said it's not hard to destroy tissue; it's hard to destroy tissue without destroying other things around [the cancer]," says J. Stephen Jones, MD, FACS.

"Now, men have the option to seek out something minimally invasive before surgical options are breached," says Denise Asafu-Adjei, MD, MPH.

In this installment of our 50th Anniversary Innovation Celebration, Anthony Zietman, MD, discusses the development of radiation therapy for prostate cancer.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Ekene A. Enemchukwu, MD, MPH, discusses the development of β3 agonists for the treatment of overactive bladder.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Denise Asafu-Adjei, MD, MPH, discusses the development of microsurgical testicular sperm extraction.

In this interview, Christopher L. Amling, MD, FACS, discusses the development of anatomic radical prostatectomy and how the technique transformed the surgical treatment of prostate cancer.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).

"The true innovation is finding better ways to do focal therapy that decreases the side effects for the patients and still treats the lesion effectively," says Jennifer A. Linehan, MD.

"We're all very aware of the impact that prostate-specific antigen [PSA] has had on screening for prostate cancer. What's underappreciated is how the biopsy technique pivoted at about the same time," says Adam S. Kibel, MD.

In this interview, Eila C. Skinner, MD, discusses neobladder reconstruction in patients undergoing radical cystectomy.

In this installment, Howard B. Goldman, MD, FACS, discusses the development of multichannel urodynamics testing.

In this interview, Justin Dubin, MD, discusses the development of treatments for male infertility.

In this interview, Simpa Salami, MD, MPH, discusses the development of urinary biomarkers in prostate cancer detection.

In this interview, Sanjay Patel, MD, discusses blue light cystoscopy for the detection of bladder cancer.

In this interview, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone agonists and antagonists in prostate cancer.

In this interview, Nitya E. Abraham, MD, discusses innovations in vesicovaginal fistula repair.

In this interview, Andrew C. Peterson, MD, MPH, discusses the development of the artificial urinary sphincter.